Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00505583|
Recruitment Status : Withdrawn
First Posted : July 23, 2007
Last Update Posted : November 29, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Methadone-maintenance Subjects||Drug: MOA-728||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||A Randomized, Double-Blind, Triple-Dummy, 3-Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Formulation of MOA-728 in Subjects on Stable Methadone Maintenance|
|Study Start Date :||July 2007|
|Estimated Primary Completion Date :||December 2007|
|Estimated Study Completion Date :||December 2007|
- To characterize the pharmacodynamics of single oral doses of MOA-728 compared to a positive control of MOA-728 administered intravenously in subjects on stable methadone maintenance.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Healthy men or women, aged 18 to 65 years.
- History of methadone treatment for at least 1 month, at a dose >=30 and <=140 mg/day.
- History or active presence of clinically important medical disease.
- Allergy to opioids.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00505583
|United States, Florida|
|Gainesville, Florida, United States, 32608|
|Study Director:||Jeff Cohn||Bausch Health Americas, Inc.|
|Responsible Party:||Jeff Cohn, Salix Pharmaceuticals|
|Other Study ID Numbers:||
|First Posted:||July 23, 2007 Key Record Dates|
|Last Update Posted:||November 29, 2019|
|Last Verified:||November 2019|